KR20210072002A - 폴리머 기반 거대분자 프로드러그 - Google Patents

폴리머 기반 거대분자 프로드러그 Download PDF

Info

Publication number
KR20210072002A
KR20210072002A KR1020217011264A KR20217011264A KR20210072002A KR 20210072002 A KR20210072002 A KR 20210072002A KR 1020217011264 A KR1020217011264 A KR 1020217011264A KR 20217011264 A KR20217011264 A KR 20217011264A KR 20210072002 A KR20210072002 A KR 20210072002A
Authority
KR
South Korea
Prior art keywords
peg
prodrug
polymer
macromolecular prodrug
macromolecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217011264A
Other languages
English (en)
Korean (ko)
Inventor
마이클 초르니
이반 알페리브
가렛 엠. 브로되르
Original Assignee
더 칠드런스 호스피탈 오브 필라델피아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 칠드런스 호스피탈 오브 필라델피아 filed Critical 더 칠드런스 호스피탈 오브 필라델피아
Publication of KR20210072002A publication Critical patent/KR20210072002A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
KR1020217011264A 2018-09-17 2019-09-17 폴리머 기반 거대분자 프로드러그 Pending KR20210072002A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732199P 2018-09-17 2018-09-17
US62/732,199 2018-09-17
PCT/US2019/051457 WO2020061007A1 (en) 2018-09-17 2019-09-17 Polymer-based macromolecular prodrugs

Publications (1)

Publication Number Publication Date
KR20210072002A true KR20210072002A (ko) 2021-06-16

Family

ID=69887739

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011264A Pending KR20210072002A (ko) 2018-09-17 2019-09-17 폴리머 기반 거대분자 프로드러그

Country Status (10)

Country Link
US (4) US11253603B2 (enExample)
EP (1) EP3852793B1 (enExample)
JP (1) JP7546552B2 (enExample)
KR (1) KR20210072002A (enExample)
CN (2) CN112996533B (enExample)
AU (1) AU2019344783B2 (enExample)
CA (1) CA3112778A1 (enExample)
EA (1) EA202190799A1 (enExample)
MX (1) MX2021003116A (enExample)
WO (1) WO2020061007A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112996533B (zh) * 2018-09-17 2025-01-10 费城儿童医院 基于聚合物的大分子前药
CN115443947B (zh) * 2022-10-12 2023-11-21 江苏省人民医院（南京医科大学第一附属医院） 高血压动物模型的制备方法
WO2025101904A1 (en) * 2023-11-08 2025-05-15 The Children's Hospital Of Philadelphia Norepinephrine transporter-targeted prodrugs for cancer therapy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052861A1 (de) * 1998-04-09 1999-10-21 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Neue benzylguanidinderivate für die therapie, in-vivo- und in-vitro-diagnostik
JP2002255821A (ja) * 2001-03-06 2002-09-11 Yakult Honsha Co Ltd 抗癌剤耐性癌に対する治療剤
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20040258754A1 (en) * 2003-06-18 2004-12-23 Valery Alakhov Compositions for oral administration of camptothecin and its analogs
KR101200729B1 (ko) 2003-09-17 2012-11-13 넥타르 테라퓨틱스 다분지형 고분자 전구약물
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CA2543722C (en) * 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2007106549A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for treating brain cancer
CA2662973A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
US20090074074A1 (en) 2007-06-29 2009-03-19 The Hong Kong University Of Science And Technology Multiple description encoder and decoder for transmitting multiple descriptions
CN102159250B (zh) * 2008-08-11 2014-08-06 尼克塔治疗公司 多臂的聚合烷酸酯偶联物
PT2349346T (pt) 2008-09-23 2019-10-24 Nektar Therapeutics Método de dosagem metronómica com profármacos de camptotecina (e.g. peg-irinotecano).
CN102215688A (zh) * 2008-10-21 2011-10-12 安龙制药公司 用7-乙基-10-羟基喜树碱的多臂聚合物对神经母细胞瘤的治疗
CN101385860B (zh) * 2008-10-31 2011-11-02 美国草药泉有限责任公司 喜树碱及其衍生物的非线性聚乙二醇前药
EP2456464A4 (en) 2009-07-22 2013-02-20 Enzon Pharmaceuticals Inc METHODS OF TREATING POSITIVE HER2 CANCER WITH HER2 RECEPTOR ANTAGONIST IN COMBINATION WITH 7-ETHYL-10-HYDROXYCAMPTOTHECIN MULTI-ARM POLYMERIC CONJUGATES
HUE043689T2 (hu) 2009-11-18 2019-09-30 Nektar Therapeutics Polimer-gyógyszer savas sói
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
CN102626518B (zh) * 2012-05-09 2014-05-28 中国药科大学 一种包载难溶性药物的泊洛沙姆/两亲性多糖混合胶束的制备和应用
CN104813167B (zh) 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
WO2014194289A1 (en) 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
US10016411B2 (en) * 2013-10-04 2018-07-10 Prolynx Llc Slow-release conjugates of SN-38
WO2015191583A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016050210A1 (zh) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物及其制备方法
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
WO2018048859A1 (en) 2016-09-06 2018-03-15 Cerebral Therapeutics Direct brain administration of chemotherapeutics to the csf for patients with primary and secondary brain tumors
AU2018255458B2 (en) 2017-04-21 2020-06-25 Brightgene Bio-Medical Technology Co., Ltd. Multi-arm targeted anti-cancer conjugate
CN111328330B (zh) 2017-09-08 2024-03-08 普罗蒙托里治疗有限公司 作为免疫调节剂的磷铂化合物及其治疗用途
WO2019090141A1 (en) 2017-11-02 2019-05-09 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
US20190375732A1 (en) 2018-05-14 2019-12-12 David Hung Anti-cancer nuclear hormone receptor-targeting compounds
CN112996533B (zh) * 2018-09-17 2025-01-10 费城儿童医院 基于聚合物的大分子前药
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
KR20220008869A (ko) 2019-05-14 2022-01-21 누베이션 바이오 인크. 항암 핵 호르몬 수용체-표적화 화합물

Also Published As

Publication number Publication date
EA202190799A1 (ru) 2021-06-22
WO2020061007A1 (en) 2020-03-26
MX2021003116A (es) 2021-05-14
CA3112778A1 (en) 2020-03-26
US11253603B2 (en) 2022-02-22
CN119950749A (zh) 2025-05-09
US20210000967A1 (en) 2021-01-07
US12311028B2 (en) 2025-05-27
US20250387496A1 (en) 2025-12-25
US20220160886A1 (en) 2022-05-26
JP2022501341A (ja) 2022-01-06
AU2019344783A1 (en) 2021-04-08
AU2019344783B2 (en) 2025-10-23
US11642414B2 (en) 2023-05-09
EP3852793A1 (en) 2021-07-28
NZ773863A (en) 2024-10-25
JP7546552B2 (ja) 2024-09-06
EP3852793B1 (en) 2025-11-19
CN112996533A (zh) 2021-06-18
CN112996533B (zh) 2025-01-10
US20230414766A1 (en) 2023-12-28
EP3852793A4 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
US12311028B2 (en) Polymer-based macromolecular prodrugs
JP4514455B2 (ja) Ｔｎｐ−４７０ポリマー複合体及びその使用
Li et al. Current drug research on PEGylation with small molecular agents
KR102087854B1 (ko) 단백질-중합체-약물 접합체
Santi et al. Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C max, and low glucuronide formation
US8088412B2 (en) Intralymphatic chemotherapy drug carriers
Fang et al. HSP32 (HO-1) inhibitor, copoly (styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: In vitro and in vivo anticancer effect
KR20160067181A (ko) 단백질-고분자-약물 접합체
JP2002511857A (ja) 抗体−酵素複合体をプロドラッグと組合せて含む薬学的組成物
KR20110075029A (ko) 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
US20230414762A1 (en) Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
EP3688008A1 (en) Castration resistant prostate cancer
CN110665009B (zh) 一种促肿瘤血管正常化纳米化吉西他滨及其应用
EA045198B1 (ru) Макромолекулярные пролекарства на полимерной основе
JP5843086B2 (ja) 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用
Gritli et al. Polymeric nanoparticles and cancer: Lessons learnt from CRLX101
US20120100218A1 (en) Intralymphatic Chemotherapy Drug Carriers
CN104981245A (zh) 无副作用的抗癌剂
WO2025101904A1 (en) Norepinephrine transporter-targeted prodrugs for cancer therapy
CN119950745B (zh) 一种药物组合物及其在制备抗肿瘤药物中的应用
Picken Prodrug approaches to reduce treprostinil toxicity
HK1214145B (en) Anticancer agent having no side effects

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902